Sold as "the tan jab," Melanotan II is one of the most heavily marketed — and most heavily warned-about — peptides on the gray market. Here's what it actually is, what the science does and doesn't show, the safety concerns that keep coming up, and exactly where it stands with the FDA in 2026.
Melanotan II (often "MT-II" or "MT-2") is a synthetic melanocortin analog — a small peptide designed to mimic α-melanocyte-stimulating hormone (α-MSH), the natural signal that tells skin cells to produce more melanin (pigment). Because it activates melanocortin receptors broadly, it has been marketed mainly for skin tanning, and separately promoted for effects on libido. It is not a vitamin, a supplement, or an approved medication.
The honest headline: Melanotan II has no approved indication anywhere in the world, and the human evidence behind the marketing claims is thin. Most of what circulates online is sold as a research chemical and labeled "not for human use." That gap between aggressive marketing and limited human data — plus some real safety signals — is exactly what this page exists to close.
Melanotan II is not an FDA-approved drug. Its compounding status moved in 2026, and the nuance matters:
Want the live picture? Our regulatory-status tracker shows exactly where Melanotan II and other peptides stand right now, with the dated primary sources.
Melanotan II does what its mechanism predicts: by activating melanocortin receptors it can increase melanin production, and early small studies explored both tanning and sexual-function effects (a related, more selective molecule was later developed specifically for the libido pathway). So the basic pharmacology is real.
But the human safety and efficacy evidence is limited. The published clinical work is small and early-phase, and there is no large, controlled body of data establishing that Melanotan II is safe over time in people. Much of what circulates online is anecdote, not data. That doesn't mean nothing happens — it means the evidence needed to call it safe and appropriate for human use largely isn't there. Treat confident before-and-after claims with skepticism.
Commonly reported subcutaneous doses land around 0.25–1 mg, almost always started very low and titrated up cautiously because of Melanotan II's side-effect profile. To be clear: these are not approved or standardized doses — they reflect what clinics and the wider community commonly report using today, shared for education, not medical advice. Given the documented safety concerns, please read the side effects & safety section below before going any further, and keep any decision with a licensed provider.
Melanotan II typically ships as a freeze-dried (lyophilized) powder that must be reconstituted with bacteriostatic water before it's a liquid. The math — concentration and the volume to draw — trips a lot of people up, and a misplaced decimal in micrograms is a 1,000× error. That's what our free tool is for:
This is where Melanotan II stands apart from many other peptides — there are documented safety concerns, and they're the reason regulators have warned against it:
On top of the molecule itself, product quality varies enormously. Because the supply is research-use-only and unregulated, purity, sterility, and accurate labeling are real concerns — which is why sourcing and testing matter as much as the molecule. None of this is fear-mongering: it's the documented picture, and it's why we treat Melanotan II as a cautionary case rather than a casual one.
If you're considering Melanotan II, the responsible path runs through a licensed provider who can weigh your situation — especially your skin and mole history — not a checkout page. Questions worth asking: Is there third-party testing and a certificate of analysis? What's the source and is it disclosed? What does the provider make of the documented mole and cardiovascular concerns, and of the current legal status? This isn't legal or medical advice — it's the baseline diligence any unapproved substance deserves, and Melanotan II deserves more than most.
Melanotan products are sold in injectable and intranasal forms, but neither is FDA-approved and both carry the same safety concerns. The delivery method doesn't change the regulatory status or the documented risks.
There's no proof it directly causes melanoma, but it stimulates melanocytes broadly and has been linked to changes in existing moles, which is why dermatologists raise concern — especially for people with a melanoma or atypical-mole history. The honest answer is that the long-term cancer risk in humans is not established, and that uncertainty is itself a reason for caution.
They're related melanocortin peptides, but afamelanotide is an approved prescription product for a specific rare condition, whereas Melanotan II is unapproved and sold gray-market for cosmetic tanning. Don't treat them as interchangeable.
We don't sell peptides and we don't direct consumers to buy unapproved substances. If a licensed provider determines it's appropriate, sourcing and testing should be part of that conversation.
Educational information only. Not medical, legal, or regulatory advice, not a dosing, treatment, or efficacy claim, and not a recommendation to obtain or use any substance. Many peptides are not FDA-approved; some are labeled research-use-only ("not for human use"). Regulatory status changes frequently — verify independently and consult a licensed provider before any health decision. Published by Health Pro Distributors. © 2026.